Praxis Precision Medicine

PRAX Mid Cap

Healthcare · Biotechnology

Updated: Apr 5, 2026, 17:43 UTC

$310.38

-2.79% today

52W: $26.70 – $356.00

52W Low: $26.70 Position: 86.1% 52W High: $356.00

🔗 Compare Brokers Best Broker for Beginners →

Key Metrics

P/E Ratio

—

Price-to-Earnings

Forward P/E

—

Forward Price/Earnings

P/S Ratio

—

Price-to-Sales

EV/EBITDA

—

Enterprise Value/EBITDA

Div. Yield

—

Annual dividend yield

Market Cap

$8.6B

Market Capitalization

Revenue Growth

—

YoY Revenue Growth

Profit Margin

—

Net profit margin

ROE

-45.83%

Return on Equity

Beta

2.97

Market sensitivity

Short Interest

13.46%

% of float sold short

Avg. Volume

491,347

Average daily volume

Valuation Analysis

Signal

N/A

vs. S&P 500 avg P/E (24.7x)

Analyst Consensus

Strong Buy

16 analysts

Avg. Price Target

$617.62

+98.99% upside

Target Range

$130.00 – $1,245.00

About the Company

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide. It also develops ulixacaltamide, a small molecule inhibitor of T-type calcium channels that in NDA for the treatment of essential tremor; relutrigine, a small molecule, which is in NDA for the treatment of SCN2A- and SCN8A-developmental and epileptic encephalopathies (DEE), as well as in Phase 3 trial for broad DEEs; vormatrigine, a small molec

Sector: Healthcare Industry: Biotechnology Country: United States Employees: 168 Exchange: NMS